DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman,
While the top- and bottom-line numbers for DexCom (DXCM) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to
Dexcom stock plunged late Thursday after the company raised its sales outlook for the year, but not enough to satisfy investors.
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #dexcom--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights:
The value of the “global medical device market” is expected to jump from over $500 billion last year to nearly $800 billion “by 2030.” According to the World Health Organization, “a medical
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Beyond analysts' top -and-bottom-line estimates for DexCom (DXCM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Dexcom stock is in a buy zone ahead of earnings next week. Shares rallied after the company launched a prescription-free glucose monitoring device.
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt gr
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE